Department of Thoracic Surgery, Peking University People's Hospital, 100044, Beijing, P.R. China.
Thoracic Oncology Institute, Peking University People's Hospital, 100044, Beijing, P.R. China.
Lung. 2023 Aug;201(4):415-423. doi: 10.1007/s00408-023-00635-5. Epub 2023 Jul 24.
The current study evaluated a large cohort of T2N0M0 NSCLC patients with different T2 descriptors to investigate the prognostic disparities and further externally validate the T category of these patients.
The Kaplan-Meier Method with the log-rank test was used to plot survival curves. The propensity score matching (PSM) method was used to reduce bias. Univariable and multivariable Cox analyses were used to determine prognostic factors.
A total of 13,015 eligible T2N0M0 NSCLC patients were included. There were 5,287, 2,577 and 5,151 patients in the T2a, T2b and non-sized determined T2N0M0 (T2non-sized) groups, respectively. Before PSM, the survival of T2non-sized patients was comparable to that of T2a patients (P = 0.080) but was superior to that of T2b patients (P < 0.001). After PSM, the survival of T2non-sized patients was inferior to that of T2a patients (P = 0.028) but was similar to that of T2b patients (P = 0.325). The T category was further subdivided based on the specific non-sized T2 descriptors and tumor size. The results of the multivariate Cox analysis found that the prognosis of T2 tumors with visceral pleural invasion (size: 0-30 mm) was better than that of T2a tumors, and the prognosis of T2 tumors with visceral pleural invasion (size: 30-40 mm) was inferior to that of T2a tumors but comparable to that of T2b tumors.
T2 tumors with visceral pleural invasion (size: 30-40 mm) should be assigned to the T2b category, and those with a size interval of 0-30 mm should be assigned to a better prognostic T2a category.
本研究评估了大量 T2N0M0 NSCLC 患者的不同 T2 描述符,以探讨预后差异,并进一步外部验证这些患者的 T 分期。
采用 Kaplan-Meier 法和对数秩检验绘制生存曲线。采用倾向评分匹配(PSM)法减少偏倚。采用单变量和多变量 Cox 分析确定预后因素。
共纳入 13015 例符合条件的 T2N0M0 NSCLC 患者。T2a、T2b 和未确定大小的 T2N0M0(T2non-sized)组分别有 5287、2577 和 5151 例患者。在 PSM 之前,T2non-sized 患者的生存与 T2a 患者相当(P=0.080),但优于 T2b 患者(P<0.001)。PSM 后,T2non-sized 患者的生存不如 T2a 患者(P=0.028),但与 T2b 患者相似(P=0.325)。根据特定的非大小 T2 描述符和肿瘤大小进一步细分 T 分期。多变量 Cox 分析结果发现,有内脏胸膜侵犯(大小:0-30mm)的 T2 肿瘤的预后优于 T2a 肿瘤,而有内脏胸膜侵犯(大小:30-40mm)的 T2 肿瘤的预后劣于 T2a 肿瘤,但与 T2b 肿瘤相当。
有内脏胸膜侵犯(大小:30-40mm)的 T2 肿瘤应归入 T2b 类,大小间隔为 0-30mm 的肿瘤应归入预后较好的 T2a 类。